Biden pushes democracy abroad. Republicans openly question it at home
Analysis by Zachary B. Wolf, CNN
President Joe Biden is girding himself for an epic confrontation of democracy vs. autocracy at his meeting with Russian President Vladimir Putin in Geneva, even as some Republicans back at home are openly questioning if democracy has much of anything to do with America at all.
The defense of democracy has so far been the ideological cause of Biden’s presidency. “This is democracy’s day,” he said in his inaugural address, promising to pursue unity at all costs and defend people’s rights to disagree.
28 May 2021
I have admittedly not heard anything new from the Portico Quartet since their superb sophomore album
Isla. When PopMatters’ own Nathan Stevens warned us all of what happened when the group dropped the ‘Quartet’ from their name and released
Living Fields, I must have assumed it was a permanent change because I just plain forgot about them. With
Terrain, the joke’s on me. Not only did they reinstate the ‘Quartet’ to their name after their brief experiment in electronic music and go back to playing highly percussive minimalist jazz, but they have also taken significant steps in transcending their highly specified subgenre.
Artelo Biosciences (NASDAQ:ARTL) stock is soaring higher on Friday after Ladenburg analyst Michael Higgins initiated coverage of the biopharma company. Source: Shutterstock The Ladenburg analyst kicks off coverage of ARTL stock with a buy rating. That matches up with the consensus buy rating for the stock. That consensus rating comes from two buy ratings for Artelo Biosciences. To go along with the positive rating from Higgins is a price target of $7 per share. That also matches up with the consensus price target for ARTL stock. It also represents a potential 329% upside over the stock’s closing price on Thursday.InvestorPlace - Stock Market News, Stock Advice & Trading Tips So what’s behind the bullish rating for ARTL stock from Ladenburg? In the letter initiating the coverage of Artelo Biosciences, Higgins points to the company’s work on developing treatments targeting the endocannabinoid system as the reason for the positive stance. 8 Cheap Stocks Under $20